- Titre
- POSTER: AML-229 Efficacy and Safety of Pivekimab Sunirine (PVEK) in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in the CADENZA Study.
- Créateurs - sans rôle
- Naveen Pemmaraju - The University of Texas MD Anderson Cancer CenterGiovanni Marconi - Istituto Scientifico Romagnolo per lo Studio e la Cura dei TumoriPau Montesinos - Hospital Universitari i Politècnic La FeAndrew Lane - Dana-Farber Cancer InstituteLuca Mazzarella - Istituti di Ricovero e Cura a Carattere ScientificoDavid Andrew Sallman - Moffitt Cancer CenterMatthew Ulrickson - The University of Texas MD Anderson Cancer CenterGary Schiller - UCLA HealthHarry Paul Erba - Duke UniversityEunice S.Wang - Roswell Park Comprehensive Cancer CenterRoland B.WalterEric Deconinck - Centre Hospitalier Universitaire de BesançonAhmed Aribi - City of HopeOllivier Legrand - Hôpital Saint-AntoineDelphine Lebon - Centre Hospitalier Universitaire Amiens-PicardieGiovanni Martinelli - Istituto Scientifico Romagnolo per lo Studio e la Cura dei TumoriDaniel Deangelo - Dana-Farber Cancer InstituteYining Du - AbbVieJalaja Potluri - AbbVieNaval Guastad Daver - The University of Texas MD Anderson Cancer Center
- Colloque
- Society of Hematologic Oncology Thirteenth Annual Meeting (Houston (Texas), United States, 03/09/2025)
- Identifiants
- 99161592809311
- Unité académique
- Cell souches plasticité cellul régénérat tissulaire immuno des maladies inflamm - IRMB
- Langue
- English
- Type de ressource
- Conference poster
- Champs locaux
- hal-05228538
Poster de colloque
POSTER: AML-229 Efficacy and Safety of Pivekimab Sunirine (PVEK) in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in the CADENZA Study.
Society of Hematologic Oncology Thirteenth Annual Meeting (Houston (Texas), United States, 03/09/2025)
09/2025
Indicateurs
1 Consultations de la notice